OTCMKTS:RCDTF Recordati Industria Chimica e Farmaceutica (RCDTF) Stock Price, News & Analysis $52.25 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest About Recordati Industria Chimica e Farmaceutica Stock (OTCMKTS:RCDTF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RCDTF alerts:Sign Up Key Stats Today's Range$52.25▼$52.2550-Day Range$52.25▼$52.2552-Week Range$52.25▼$52.25VolumeN/AAverage Volume2 shsMarket CapitalizationN/AP/E Ratio26.13Dividend YieldN/APrice TargetN/AConsensus RatingReduce Company OverviewRecordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.Read More… When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Receive RCDTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recordati Industria Chimica e Farmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address RCDTF Stock News HeadlinesRecordati’s Strategic Share Buyback InitiativeNovember 21 at 3:18 AM | markets.businessinsider.comRecordati Completes Share Buy-Back ProgramNovember 12, 2024 | markets.businessinsider.comTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.November 21, 2024 | Angel Publishing (Ad)Recordati Launches Share Buy-Back Program to Boost IncentivesNovember 12, 2024 | markets.businessinsider.comItaly's Recordati sees no impact from potential US pharma tariffsNovember 9, 2024 | msn.comRecordati Enhances Share Value with Buyback ProgramNovember 7, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS)November 6, 2024 | markets.businessinsider.comRecordati Advances in Share Buyback ProgramOctober 30, 2024 | markets.businessinsider.comSee More Headlines RCDTF Stock Analysis - Frequently Asked Questions How have RCDTF shares performed this year? Recordati Industria Chimica e Farmaceutica's stock was trading at $46.00 at the start of the year. Since then, RCDTF shares have increased by 13.6% and is now trading at $52.25. View the best growth stocks for 2024 here. How do I buy shares of Recordati Industria Chimica e Farmaceutica? Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:RCDTF Previous SymbolNASDAQ:RCDTF CUSIPN/A CIKN/A Webwww.recordati.com Phone390-248-7871Fax39-02-4007-3747Employees4,455Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$2.00 Trailing P/E Ratio26.13 Forward P/E RatioN/A P/E GrowthN/ANet Income$421.25 million Net Margins17.41% Pretax MarginN/A Return on Equity30.78% Return on Assets12.65% Debt Debt-to-Equity Ratio0.73 Current Ratio1.36 Quick Ratio0.95 Sales & Book Value Annual Sales$2.25 billion Price / SalesN/A Cash Flow$3.06 per share Price / Cash Flow17.08 Book Value$7.90 per share Price / Book6.61Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.34 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (OTCMKTS:RCDTF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recordati Industria Chimica e Farmaceutica S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recordati Industria Chimica e Farmaceutica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.